Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma

PLoS One. 2020 Feb 6;15(2):e0228544. doi: 10.1371/journal.pone.0228544. eCollection 2020.

Abstract

Background: The individual and combined contribution of viral prevalence in the community to Emergency Department (ED) visits and hospitalizations with respiratory tract infections (RTIs), chronic obstructive pulmonary disease (COPD) and asthma is unclear.

Methods: A retrospective analysis on daily viral positive tests and daily ED visits and hospitalizations between 01/01/2003 to 31/12/2013 in Ontario, Canada. Viral data was collected from the Centre for Immunization and Respiratory Infectious Diseases (CIRID). The Canadian Institute for Health Information reports daily ED visits and hospitalizations for RTIs, COPD and asthma as a primary diagnosis.

Results: There were 4,365,578 ED visits with RTIs of which 321,719 (7.4%) were admitted to hospital; 817,141 ED visits for COPD of which 260,665 (31.9%) were admitted and 649,666 ED visits with asthma of which 68,626 (10.6%) were admitted. The percentage of positive tests to influenza A and B, respiratory syncytial virus (RSV), parainfluenza and adenovirus prevalence explained 57.4% of ED visits and 63.8% of hospitalizations for RTI, 41.4% of ED visits and 39.2% of hospitalizations with COPD but only 1.5% of ED visits and 2.7% of hospitalizations for asthma. The further addition of human metapneumovirus, rhinovirus and coronavirus over the final 3 years accounted for 66.7% of ED visits and 74.4% of hospitalizations for RTI, 52.5% of visits and 48.2% of hospitalizations for COPD, and only 13.3% of visits and 10.4% of hospitalizations for asthma.

Conclusions: Community respiratory viral epidemics are major drivers of ED visits and hospitalizations with RTIs and COPD but only a modest contributor to asthma.

Publication types

  • Historical Article
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asthma / complications
  • Asthma / epidemiology*
  • Community-Acquired Infections / epidemiology
  • Emergency Service, Hospital* / statistics & numerical data
  • History, 21st Century
  • Hospitalization / statistics & numerical data*
  • Hospitalization / trends
  • Humans
  • Ontario / epidemiology
  • Prevalence
  • Pulmonary Disease, Chronic Obstructive / complications
  • Pulmonary Disease, Chronic Obstructive / epidemiology*
  • Respiratory Tract Infections / epidemiology*
  • Retrospective Studies
  • Virus Diseases / epidemiology*

Grants and funding

The research reported in this article was funded by an unrestricted grant from AstraZeneca Canada to PMO. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.